Therapy of Advanced B-Lymphoma Xenografts With a Combination of 90y-Anti-Cd22 IgG (Epratuzumab) and Unlabeled Anti-Cd20 IgG (Veltuzumab)
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0404
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2008
Authors
Publisher
American Association for Cancer Research (AACR)